Morinidazole

As a third-generation nitroimidazole anti-anaerobic drug, morphinidazole exerts antibacterial activity by inhibiting pathogen DNA synthesis. Its antibacterial activity against common anaerobic bacteria such as Bacteroides fragilis and Clostridium perfringens is superior to that of previous drugs of the same class, and the incidence of central nervous system adverse reactions is significantly reduced. It is mainly used clinically to treat anaerobic infectious diseases such as gynecological pelvic inflammatory disease and post-abdominal surgery infection. The applicable population covers the prevention and treatment of postoperative infections in adults, especially suitable for patients intolerant to metronidazole and tinidazole, and it is one of the recommended options for sequential therapy of anaerobic infections at present.

The market size of anti-anaerobic drugs in China exceeded 9 billion yuan in 2023, with nitroimidazoles accounting for more than 65%. Among them, morphinidazole, as a new-generation variety, has achieved a compound annual market growth rate of 28.7% in the past three years, with a growth rate far exceeding that of the first-generation metronidazole and the second-generation tinidazole. In the current market, generic drugs account for more than 60%, the provinces covered by local centralized procurement continue to expand, the price system is gradually stabilizing, and the demand for high-quality APIs from downstream preparation enterprises continues to rise.

The original research enterprise of morphinidazole is Jiangsu Hansoh Pharmaceutical Group Co., Ltd., with the trade name "Mailingda". Its core compound patent expires in 2026. Currently, the main dosage form approved in China is morphinidazole and sodium chloride injection, with the specification of 100ml: 0.5g morphinidazole and 0.9g sodium chloride. This variety has been included in the *Catalogue of Reference Preparations of Chemical Drugs* issued by the National Medical Products Administration. At present, there are A-status registration numbers of 3 enterprises including Hansoh Pharmaceutical on the domestic API registration platform, and the corresponding preparation varieties have all been included in the Class B medical insurance catalogue. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for morphinidazole, with most products in stock. Orders for in-stock products placed before 16:00 will be shipped on the same day. The products fully meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can provide stable reference standard support for API R&D, quality research and consistency evaluation.